Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial - Wikidata - wikimedia - TriplyDB

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

http://www.wikidata.org/entity/Q28972231

about

Visceral Leishmaniasis and HIV coinfection in East Africa Recent developments and future prospects in the treatment of visceral leishmaniasis The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis Metalloid compounds as drugs Leishmaniasis in Uganda: historical account and a review of the literature Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh.Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics.Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.An update on pharmacotherapy for leishmaniasis International Clinical Trial Day and clinical trials in Ethiopia and Africa Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups.Sterol 14α-demethylase mutation leads to amphotericin B resistance in Leishmania mexicana.Liposomal amphotericin B as a treatment for human leishmaniasis Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.Therapeutic options for visceral leishmaniasis.The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya.Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme Drug resistance in leishmaniasis: Newer developments.Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?Drug delivery: lessons to be learnt from Leishmania studies.New approaches from nanomedicine for treating leishmaniasis.Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatment.Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.Chemotherapy of leishmaniasis: present challenges.Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.Visceral leishmaniasis: a forgotten epidemic.A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan.Research for universal health coverage.Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.Antileishmanial Efficacy and Pharmacokinetics of DB766-azole Combinations.

P2860

Q24290704-84A293E3-85DE-4AE3-87D1-A74F423AB3E8 Q26740563-F0B7F1AC-2F0A-4645-A06C-E255FD82FC08 Q26748568-601146D4-3DCB-4238-90DE-6A43E3F580E8 Q26822682-9DCF89D6-5E69-4684-9D16-2413372FD184 Q26830527-BCA30605-3444-4BCA-931F-6E789A2C0512 Q27011766-378C1923-9148-4F61-A32A-86FD5ABF90A0 Q28539053-9461C37E-0EA1-4CB7-A397-CB2F473EC575 Q28550474-AAABB9E4-56F3-46EC-AF20-B5807543ABF3 Q28554069-0C2AE1C8-AEF8-40EA-8E76-68CB1A05E3C6 Q30275257-153668C4-EE92-402B-B5A1-D22D219C9865 Q30388445-4DCA2A62-DC49-4C3F-868F-29EE15EEC4E6 Q33764787-381ED036-6968-408E-84E4-5BF0F69AA4B4 Q33898691-A61E5DB7-AF91-4180-9041-7D47C1E6870F Q34328882-7C9DB015-12C4-4540-96E9-562506548B66 Q34509079-9029BF9B-62D3-434D-8540-A61344F43B22 Q34945204-C33F6179-D2FB-411A-BADF-13B058C78A7D Q34990958-30444DF0-38DA-41B5-8A5B-2475B7B83B3D Q36287224-CA431A69-58EE-4B59-AC9C-C03B66C3B796 Q36407342-F149B0A4-43F4-48E2-8607-6D380DFF1862 Q36456032-CA1DB8F5-6352-4B15-88F8-E2DBE95B64A1 Q37053235-B591DDAF-6458-41FC-B012-696CCA76960C Q37333942-B4DC783F-160E-4F3A-B515-A9A0718AD8D0 Q37372627-80D17870-A2E7-4057-B5F3-0AEBCE661430 Q37456142-94D6F85C-007A-4A89-99CC-7A5C15E1A869 Q37650681-013D1F6A-8AE0-4FD2-9F5D-A398B919A84C Q37712190-17A920BF-6142-445E-99D9-2F81AE4B1691 Q37712995-9A29657F-FF10-4B47-B365-C07DF3C98588 Q38108301-1A26BBEA-96A1-4F9D-8BF1-A519E80F9EE0 Q38209866-CA1B2ED8-5206-43A7-9174-C08C3D8AAD4F Q38254087-93CB75F8-FC95-459B-8C37-3E2B7F442EF3 Q38612712-A292ACE7-E1BC-4B3E-8DE2-435118CEC499 Q38850078-ED4876A1-DD82-485F-B27E-91FE396DFDEC Q38882958-DF13D8E7-A82B-473D-9104-0A02621EB938 Q39011875-034DD8D8-7828-406C-9B50-15268DC7287D Q39526125-81BA9546-D96A-40DF-BC35-FEB94F44B0AD Q39632056-383F4F95-624E-4330-8E67-82F5E63AA693 Q41992292-CC3E23E1-C8A7-4C38-B008-03A9F66E1EA0 Q43684264-69DC82DC-E245-4D47-8F37-6C556BA67851 Q46380663-6EF09760-4DFC-4C72-8C43-D3B726021D8C Q46430242-496638D9-EB08-4B46-A8B7-01B6D4880C81

P2860

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

http://www.wikidata.org/entity/Q28972231

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@ast

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@en

type

label

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@ast

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@en

prefLabel

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@ast

Sodium Stibogluconate (SSG) & ...... A Randomised Controlled Trial

@en

P1433

Q28972231-0A15C496-2213-417B-BC16-DD85D58539FB

P1476

Q28972231-A93D1122-D98A-4EE7-A6B1-41219060DD70

P2093

Q28972231-0F0270E0-5D96-40E8-BA84-D7DA34BA7870

Q28972231-129AE853-82FD-429A-AC4F-BFD888B2A2E4

Q28972231-130F2BE7-2BB3-499D-9924-DA3C9873663A

Q28972231-195528F3-8D1F-4D0A-AB2F-820EC02FC991

Q28972231-19B764A9-B428-46BF-90F9-33C5FFA1BCBB

Q28972231-28D89732-C108-4C80-B6DE-F761C14FF0D8

Q28972231-31841871-2EFC-475F-A1B3-7866649D065B

Q28972231-3468BC82-1A43-426A-BE9D-5A8F7922A88B

Q28972231-39EBA9F0-C603-4826-B09E-4E7A5C7A4959

Q28972231-4649CD53-CDAB-4188-9BA1-2419693E3003

P275

Q28972231-EF207984-A4EF-4AA0-B431-9D06553AF4A8

P2860

Q28972231-0AE3F682-E45D-4775-84FD-210C895EF54F

Q28972231-21168064-87E4-4490-984D-BBE46262B64D

Q28972231-23AE25FE-C7DE-4002-BEFE-B792F4095D42

Q28972231-3A844F30-6D54-4196-AA54-E5762F8A4F2E

Q28972231-45E47DBC-F8A0-4E8F-8F05-498B393FA5C4

Q28972231-4B1A7DBA-A98A-4BB0-882D-98C708822892

Q28972231-66C31227-D5B9-4139-835F-C1037FE9E186

Q28972231-6FD814B4-40AF-4374-ACA3-72D91D2580C6

Q28972231-800CC836-AD8D-4960-A62F-BDBDF046D183

Q28972231-A681F476-221E-4DAB-9CB0-27C6E40204FC

P304

Q28972231-D10246D4-F3C5-45BD-A54F-CF939101E106

P31

Q28972231-750F1BEF-4210-4DA6-B8E4-54A042AE9FE1

P3181

Q28972231-8EC903B3-C52C-4DC2-9219-719302493B02

P356

Q28972231-2E2B669C-D923-4E61-9C10-D2FEE0BFB264

P407

Q28972231-FBD462BF-7968-4CEF-ABDA-3291FD1D5E05

P433

Q28972231-4E5EB062-DA69-45EF-B5F8-B6BB4B996E73

P478

Q28972231-2EDCCD33-7E9F-4947-A239-CC4FE060A795

P50

Q28972231-A34EE27C-4655-4E95-A88D-5997E8E4B6AF

Q28972231-E52E7806-64CF-474D-ACEC-BE8727983E5C

P5008

Q28972231-73941E33-5A62-46ED-A45A-1BD0B5FFEAD3

P577

Q28972231-18327559-E097-4BA9-95AF-8737A5F15D14

P5875

Q28972231-F5715777-DB0A-4332-990C-8F3E6D316661

P698

Q28972231-5F88725D-F759-4523-B2DE-89657FB2CB33

P921

Q28972231-65741869-1D1D-48EF-8ACE-5D4BBAE52FEC

Q28972231-6BC08E57-2031-4D32-9B07-80B226405DF2

P932

Q28972231-878B6317-C79D-415B-9340-7DF3164550A7

P3181

P356

JOURNAL.PNTD.0001674

P1433

PLOS Neglected Tropical Diseases

P1476

Sodium stibogluconate (SSG) & ...... a randomised controlled trial

@en

P2093

Abuzaid Abdalla Abuzaid

http://www.w3.org/2001/XMLSchema#string

Ahmed El-Hassan

http://www.w3.org/2001/XMLSchema#string

Ahmed Fadlalla

http://www.w3.org/2001/XMLSchema#string

Ahmed Musa

http://www.w3.org/2001/XMLSchema#string

Asrat Hailu

http://www.w3.org/2001/XMLSchema#string

Brima Musa

http://www.w3.org/2001/XMLSchema#string

Dedan Mutea

http://www.w3.org/2001/XMLSchema#string

Geoffrey Mucee

http://www.w3.org/2001/XMLSchema#string

Geoffrey Mutuma

http://www.w3.org/2001/XMLSchema#string

George Kirigi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial

Drug resistance in leishmaniasis

The medical dictionary for regulatory activities (MedDRA).

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Injectable paromomycin for Visceral leishmaniasis in India.

The relationship between leishmaniasis and AIDS: the second 10 years

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.

Visceral leishmaniasis in eastern Africa--current status.

Development of a WHO growth reference for school-aged children and adolescents

P304

e1674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

997040

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0001674

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227858451

http://www.w3.org/2001/XMLSchema#string

P698

22724029

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

3378617

http://www.w3.org/2001/XMLSchema#string